Gossip Girl and Buffy the Vampire Slayer actress Michelle Trachtenberg, 39, was found dead Wednesday, February 26, in her New ...

Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the fourth quarter and year-end 2024 and ...

It was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and ...

In 2015, the Chinese Society of Hepatology and the Chinese Society of Gastroenterology published a consensus on primary ...

The global primary biliary cholangitis therapeutics market size was valued at US$732.5 million in 2023 and is projected to reach US$1358.1 billion by 2032, growing at a CAGR of 7.1% from 2024 to 2032.

Ctexli’s approval further entrenches Mirum as a leader in rare liver diseases, alongside its cornerstone product Livmarli and ...

Gilead Sciences’ seladelpar has been granted conditional marketing authorisation by the European Commission (EC) to treat ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

Gilead Sciences, Inc. has received conditional marketing authorization from the European Commission (EC) for Seladelpar for the treatment of primary biliary cholangitis (PBC) ...

Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...

Gilead Sciences’ seladelpar has won conditional marketing authorization to treat primary biliary cholangitis (PBC) alongside ...